Introduction
Low anterior resection (LAR) with total mesorectal excision is the gold standard surgical procedure for patients with resectable primary rectal cancer [
1]. When intestinal continuity with a colorectal or coloanal anastomosis is restored, the procedure is often routinely combined with a temporary stoma, to mitigate potential severe sequelae of an anastomotic leak [
2]. In general patients have a defunctioning stoma for 3–6 months, however it is not unusual that this period extends beyond 12 months prolonging the negative impact that the presence of an ileostomy has on the patient’s physical, psychological and social wellbeing [
3‐
5].
In patients with a functioning anastomosis, impaired bowel function is a frequent problem with a major impact on quality of life [
6,
7]. The symptoms are often referred to as low anterior resection syndrome (LARS), and include; urgency, difficulty emptying and incontinence [
8]. A recent meta-analysis found a combined prevalence of major LARS of 41% at least 1 year after stoma closure, when further improvement of the symptoms is unlikely [
7]. Radiotherapy and the level of the anastomosis are known to have a negative impact on major LARS, but the presence of an ileostomy and prolonged time to ileostomy closure are mentioned as possible risk factors [
9]. However, the literature is inconsistent, with few studies reporting on functional outcome after LAR with and without ileostomy.
Therefore, we performed a systematic review and meta-analysis of the current literature to evaluate the impact of a defunctioning loop ileostomy on bowel function after LAR for rectal cancer. A secondary aim was to assess whether time to stoma closure after the index operation had an effect on bowel function.
Materials and methods
Study selection
This systematic review and meta-analysis was conducted in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines (available at. Prisma-statement.org) [
10]. Comprehensive literature searches were conducted using PubMed, Embase and Cochrane databases for articles published from 1989 up to August 2019. The full search strategy is displayed in the Appendix: Table S1–3.
Studies were considered for inclusion if they met the following criteria: (1) patients diagnosed with rectal cancer within 15 cm from the anal verge; (2) patients had LAR with a colorectal or coloanal anastomosis with or without defunctioning ileostomy; (3) assessment of bowel function following LAR with a validated tool; (4) studies were cohort, case matched studies or randomized clinical trials. The exclusion criteria were as follows: (1) reviews, letters, expert opinions, commentaries, case series or case reports; (2) language other than English; (3) lack of the sufficient data or outcomes of interest; (4) duplicate studies; (4) intersphincteric resection.
Two reviewers (IV and NR) independently reviewed titles and abstracts, followed by full text revision. Additionally, the references of relevant studies were hand-searched. Authors of relevant conference abstracts or of studies with missing data were contacted to request more details, 3 authors responded and were able to provide their data sets which made inclusion in our meta-analysis possible [
1,
11,
12]. Disagreements were resolved by consensus discussion between the two reviewers (IV and NR).
Data extraction and quality assessment
Data were extracted independently by two authors (IV and NR) and included the following variables: year of publication, country, study design, number of patients, characteristics of included patients, neoadjuvant treatment, distance of the tumor from the anal verge, proportion of patients undergoing partial mesorectal excision, percentage of anastomotic leaks, number of ileostomies, time to ileostomy closure, length of follow -up and reported scoring systems to assess bowel function.
The primary outcome was bowel function after LAR for rectal cancer in patients with and without an ileostomy and also LARS as a function of time of ileostomy closure.
Risk of bias was assessed using the Newcastle-Ottowa scale for cohort studies and Jadad scoring system for randomized controlled trials [
13,
14]. When randomized groups of the randomized controlled trials (RCTs) were not used as described in the RCT, the Newcastle Ottawa quality assessment was used. Two of the authors (IV and NR) performed the quality assessment, and conflicts were discussed to achieve consensus.
Statistical analysis
Heterogeneity was assessed using the I2 and X2 statistics, the data were considered significant if the p value (X2) was < 0.1 with low, moderate, and high for I2 values of 25%, 50%, and 75%. Analysis was performed using Review Manager (RevMan, version 5.3. Copenhagen: The Nordic Centre, the Cochrane Collaboration, 20) with a random-effects model. The Mantel–Haenzel method was used to calculate the odds ratio and Inverse Variance method was used to calculate the mean difference, both illustrated in forest plots with a 95% confidence interval. When a median time to closure was presented with an interquartile range the our method was used to covert to mean time to closure with a standard deviation.
Discussion
In this systematic review and meta-analysis, we evaluated the impact of a defunctioning stoma, and time to stoma closure on bowel function after LAR for rectal cancer. The risk of developing major LARS was higher when a patient has had a defunctioning ileostomy compared to patients without an ileostomy. A prolonged time to ileostomy closure was associated with an increased incidence of major LARS.
The included studies were from Australia, China, the Netherlands, the United Kingdom, Spain and Sweden and therefore represent a wide geographical area. All included studies, with the exception of the study by Hughes et al. [
1], have at least a follow-up time of 1 year. It has been demonstrated that bowel dysfunction improves over time, but the improvement is limited after one year, thus these results reliably represent bowel function outcome after LAR [
21,
28].
A recent systematic review compared bowel function between patients undergoing LAR with and without ileostomy and outcomes for early versus later ileostomy closure [
29]. Keane et al. included only four studies that assessed bowel function, and three of the four studies were from the same cohort of patients [
11,
12,
18,
30]. A pooled analysis was performed with two of the included studies which showed a twofold increase in the rate of major LARS in patients with an ileostomy (OR 1.96, 95% CI, 1.1–3.5,
p = 0.02). This is in line with the results of our analysis, although through collection of raw data we were able to perform a pooled analysis that included six studies and showed an even stronger effect of an ileostomy on the risk of major LARS (OR 2.84, 95% CI, 1.70–4.75,
p < 0.0001). Keane et al. report that they were unable to perform a meta-analysis on the influence of timing of ileostomy closure on bowel function.
The association between LARS and presence of an ileostomy could be due to a variety of reasons; an ileostomy is more likely to be created in low anastomoses and those patients are more likely to receive neoadjuvant therapy, which have both been shown to be associated with LARS [
9]. The contribution of the length of the remnant rectum to post-operative function might be due to the interruption of the complex physiology of bowel motility and rectoanal coordination [
19]. Suggested mechanisms for how radiotherapy impacts bowel function include nerve damage, impairment of the anal sphincter, and decreased neorectal compliance caused by radiation-induced fibrosis [
15]. Nonetheless an ileostomy might have an independent influence on the LARS score. In the EASY trial (2019), the risk of major LARS was increased when there was a prolonged time to closure and results remained similar after adjusting for tumor height and use of radiotherapy [
11] and several studies reported that both radiotherapy, tumor height as well as the presence of a defunctioning stoma were independent predictors of worse LARS score [
15,
16].
Anastomotic leak has been mentioned as a risk factor for developing major LARS [
4]. Patients who have an anastomotic leak will often have an ileostomy for a more prolonged period before closure. Of the included studies in our review, 5 assessed the association between an anastomotic leak and LARS where none of the studies confirmed a correlation [
1,
12,
15,
17,
22]. In addition the prevalence of major LARS in almost 50% of the patients is much higher than the reported percentages of anastomotic leak, ranging from 0%–12.7% in the included studies. The low numbers of anastomotic leak might contribute to the lack of a significant impact on LARS score due to a type II error. Furthermore, anastomotic leak rates might be underreported in the presence of a covering stoma, when an asymptomatic leak might be present. Results from the Dutch SNAPSHOT study showed an increase in anastomotic leak within 30 days from 8.2% to 13.4%, when retrospectively checking data from the registry, which increased to 20% at end of follow-up after occult leaks were found during stoma reversal [
31].
Other findings pertaining to LARS include changes in the functional state of the pelvic floor and the sphincter complex during and after a LAR [
32]. When not used for a prolonged period of time, in a defunctioned state, pelvic floor muscles are likely to lose strength and bowel function might be impaired as a result. This is in line with a systematic review by Visser et al. that demonstrated that the use of pelvic floor rehabilitation was useful for improving functional outcome after LAR [
33].
Another reason for the association between an ileostomy and major LARS may be due to alterations in colonic environment and microbiota. There is loop ileostomy-mediated fecal stream diversion which alters microbiota composition, which in turn affects intestinal epithelial cell turnover and consequently impacts on intestinal structure and function [
34]. One study comparing colonic flora of patient with and without an ileostomy found that the abundance of several types of bacteria differed significantly between the ileostomy and control groups [
35]. This could be an explanation for the presence and duration of an ileostomy being an influence on the prevalence of major LARS.
Most surgeons aim to reverse a stoma within 2–4 months after initial surgery, but the scheduling of stoma closure is extremely variable among hospitals [
11,
36]. There are reports that it is safe to close a defunctioning stoma within 2 weeks after surgery, with a similar rate in post-operative complications and anastomotic leaks compared to delayed closure [
37]. In the United Kingdom, the national bowel cancer audit reported that up to 40% of patients had a delay in closure of more than 18 months, which is confirmed in the CLOSE-IT trial [
5]. None of the included studies reported on reason for delay in stoma closure. In previous reports, adjuvant chemotherapy is mentioned as a potential reason for delay, but when comparing patients who underwent closure of an ileostomy either during adjuvant chemotherapy or after chemotherapy a large Korean study found that post-operative hospital stay, post-operative complications, and disease free survival were equal in both groups [
38]. While clinical factors might preclude timely closure, different healthcare systems with different reimbursement/funding and logistics will have a varying average in their time to stoma closure [
39]. Currently there is a lack of guidance on the optimal timing of stoma closure.
There are some limitations to this systematic review. None of the included studies had a pre-study power calculation performed for this review’s primary outcome variable. Within the randomized controlled studies, the assessment of bowel function after an ileostomy was part of a post-hoc analysis. The majority of the studies included were cohort studies without clear guidelines on when to defunction the anastomosis with a risk of selection bias. The decision to create an ileostomy is often left to the surgeon's discretion, and patients with an ileostomy might have a lower anastomosis, more complex surgery, and/or neoadjuvant therapy. This could explain the moderate heterogeneity between the included studies in our meta-analysis comparing LARS in patients with and without ileostomy. Furthermore, none of the studies reported on the effect of patient related factors such as body mass index and age on bowel function, nor was the influence of operative time addressed as indicator of the complexity of the surgery.
Finally there were five different tools used to assess bowel function though many more are described in the literature, which makes comparison between different studies difficult. The most commonly reported was the LARS score, a score specifically designed for rectal cancer patients after LAR [
40]. However this score is thought to underestimate evacuatory dysfunction and may not accurately assess the impact of symptoms on individual patient’s quality of life [
41]. The interpretation of the LARS score results is also limited by the findings that major LARS is also common in the general population without rectal cancer, especially in women between 50 to 79 years old [
42]. A new LARS score is being developed but so far optimal scoring systems to assess bowel function after LAR are lacking [
41].
The cause of poor bowel function after rectal cancer surgery is multifactorial. Further studies assessing the pathophysiology of the association an ileostomy and major LARS and influence of timing on ileostomy closure are required with bowel function as primary outcome of the study.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.